Skip to main content

Table 1 Characteristics of all patients

From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Characteristic T + C (n = 50) T (n = 67) p
Age (years)    0.294
 Median (range) 59(36–81) 61(40–84)  
Sex    0.506
 Male 24(48.00%) 28(38.27%)  
 Female 26(52.00%) 39(61.73%)  
Histology    1.000
 Adenocarcinoma 50(100.00%) 67(100.00%)  
ECOG PS    0.835
 0–1 49(98.00%) 66(98.77%)  
 2 1(2.00%) 1(1.23%)  
Smoking history    0.986
 Nerve 35(70.00%) 47(72.84%)  
 Former 15(30.00%) 20(27.16%)  
EGFR mutation    0.321
 Exon 19 deletion 26(52.00%) 41(55.56%)  
 L858R 21(42.00%) 23(38.27%)  
 Others 3(8.00%) 3(6.17%)  
Brain metastasis    0.345
 Yes 9(18.00%) 17(23.46%)  
 No 41(82.00%) 50(76.54%)  
Stage    0.713
 IIIb/IIIc 3(6.00%) 3(3.70%)  
 IV 47(94.00%) 64(96.30%)  
Cardiovascular    
 Hypertension 15(30.00%) 21(31.34%) 0.877
 Coronary heart disease 0(0.00%) 1(1.23%) 0.388
 Cerebrovascular disease 0(0.00%) 2(2.99%) 0.220
Metabolic    
 Diabetes 6(12.00%) 6(8.96%) 0.593
 Hyperlipidemia 2(4.00%) 1(1.23%) 0.398
 Hyperuricemia 0(0.00%) 1(1.23%) 0.388